This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.
TAK-653 is a novel positive allosteric modulator (PAM) of AMPA-type glutamate receptors developed by Takeda Pharmaceuticals. It enhances glutamatergic neurotransmission without directly activating the receptor, offering a more controlled mechanism for cognitive enhancement and antidepressant effects.
TAK-653 acts as a positive allosteric modulator (PAM) of AMPA receptors, binding to a site distinct from the glutamate binding site. It increases the receptor's sensitivity to glutamate, enhancing excitatory postsynaptic currents (EPSCs) and promoting long-term potentiation (LTP) — the cellular basis of learning and memory. Unlike direct AMPA agonists, PAMs like TAK-653 only enhance signaling when glutamate is naturally released, reducing the risk of excitotoxicity. It also promotes BDNF release and downstream mTOR/TrkB signaling pathways involved in synaptic plasticity and dendritic growth.
TAK-653 acts as a positive allosteric modulator (PAM) of AMPA receptors, binding to a site distinct from the glutamate binding site. It increases the receptor's sensitivity to glutamate, enhancing excitatory postsynaptic currents (EPSCs) and promoting long-term potentiation (LTP) — the cellular basis of learning and memory. Unlike direct AMPA agonists, PAMs like TAK-653 only enhance signaling when glutamate is naturally released, reducing the risk of excitotoxicity. It also promotes BDNF release and downstream mTOR/TrkB signaling pathways involved in synaptic plasticity and dendritic growth.
TAK-653 is a novel positive allosteric modulator (PAM) of AMPA-type glutamate receptors developed by Takeda Pharmaceuticals. It enhances glutamatergic neurotransmission without directly activating the receptor, offering a more controlled mechanism for cognitive enhancement and antidepressant effects. Originally developed for treatment-resistant depression, it has gained interest in the research community for its potential nootropic and neuroplasticity-promoting properties.
IUPAC Name
Not yet available
CAS Number
1531665-83-2
Molecular Formula
C16H11FN2O2
Molecular Mass
282.27 g/mol
Create a free account to:
Join 2,800+ researchers
Create a free account to:
Join 2,800+ researchers
History of seizure disorders or epilepsy. Concurrent use of other glutamatergic agents or excitatory compounds. Traumatic brain injury (acute phase). Pregnancy or breastfeeding. Known hypersensitivity to benzamide derivatives.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for TAK-653.
Nootropics
9-Methyl-β-carboline (9-MBC) is a synthetic β-carboline alkaloid that has gained significant interest in the nootropic community for its reported ability to promote dopaminergic neuron growth, increase dopamine synthesis enzymes, and provide neuroprotective effects against neurotoxins.
Nootropics
Alpha-GPC (L-alpha glycerylphosphorylcholine) is a choline-containing phospholipid naturally present in the brain and found in small amounts in dairy and meat.
Nootropics
Bromantane (Ladasten) is an atypical psychostimulant and anxiolytic developed in Russia, approved there for asthenia.
Nootropics
CDP-Choline (cytidine diphosphocholine, citicoline) is a naturally occurring nucleotide found in every cell in the body, and one of the most evidence-backed nootropics available.
Nootropics
Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
Nootropics
Lion's Mane (Hericium erinaceus) is a medicinal mushroom with a growing body of clinical evidence for cognitive enhancement, neurogenesis, and nerve repair.
View Full Dosage Guide →
Protocols, calculator & safety for TAK-653
0 PubMed studies
Data Completeness
75%Half-Life
6-10 hours (estimated)
Molecular Weight
282.27 g/mol
Administration
Oral
CAS Number
1531665-83-2
Trial Phase
Phase II Clinical Trials
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
TAK-653 is a novel positive allosteric modulator (PAM) of AMPA-type glutamate receptors developed by Takeda Pharmaceuticals. It enhances glutamatergic neurotransmission without directly activating the receptor, offering a more controlled mechanism for cognitive enhancement and antidepressant effects. Originally developed for treatment-resistant depression, it has gained interest in the research community for its potential nootropic and neuroplasticity-promoting properties.
TAK-653 is available in vials, capsules, and sprays forms.
Pricing varies by vendor and form.
Compare prices, payment methods, shipping, and COA scores across 0 vendors.
Nootropics
9-Methyl-β-carboline (9-MBC) is a synthetic β-carboline alkaloid that has gained significant interest in the nootropic community for its reported ability to promote dopaminergic neuron growth, increase dopamine synthesis enzymes, and provide neuroprotective effects against neurotoxins.
Nootropics
Alpha-GPC (L-alpha glycerylphosphorylcholine) is a choline-containing phospholipid naturally present in the brain and found in small amounts in dairy and meat.
Nootropics
Bromantane (Ladasten) is an atypical psychostimulant and anxiolytic developed in Russia, approved there for asthenia.
Nootropics
CDP-Choline (cytidine diphosphocholine, citicoline) is a naturally occurring nucleotide found in every cell in the body, and one of the most evidence-backed nootropics available.
Nootropics
Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
Nootropics
Lion's Mane (Hericium erinaceus) is a medicinal mushroom with a growing body of clinical evidence for cognitive enhancement, neurogenesis, and nerve repair.